SpliceCore is Envisagenics' proprietary AI/ML platform that enables the translation of vast amounts of RNA sequencing data into novel therapeutics. SpliceCore's versatility extends to both the ...
The British drugmaker has bolstered its business with nearly $5 billion in acquisitions as attention turns to its pipeline of experimental medicines.
The cuts of four pipeline prospects come as BioMarin resets its priorities following the slow launch of its hemophilia gene therapy Roctavian.